PPCB News & Events

Propanc Biopharma announced highlights of PRP, its lead proenzyme therapy. The company said, "Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game: 85% tumor growth inhibition demonstrated in preclinical pancreatic models; Forces malignant cells to differentiate-attacking cancer at its root; Reduces fibrosis and resistance markers in the tumor microenvironment; Sensitizes resistant tumors to standard chemo-higher efficacy, lower toxicity; Targets cancer stem cells to cut recurrence risk"

Propanc Biopharma announced that management has executed a service agreement with FyoniBio, a German Contract Development Organization, CDO, based in Berlin for establishing and validating a liquid chromatography-mass spectrometry, LC-MS, based pharmacokinetics, PK, assay. The objective is to quantify the Company's lead asset, PRP, consisting of two proenzymes trypsinogen and chymotrypsinogen, as well as their activated enzyme forms trypsin and chymotrypsin from human serum during the Phase 1b, First-In-Human, FIH, study in advanced cancer patients suffering from solid tumors.

Propanc Biopharma highlights the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metastatic cancer from solid tumors, especially more aggressively spreading, less differentiated tumors, which offer a poor patient prognosis. Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate stuck at just 13% and no real progress has been made in recent years. To put that into perspective, overall cancer survival is 70%. Standard treatments like chemotherapy, targeted therapies, and emerging options extend life modestly but often bring harsh side effects, resistance, and limited success against this aggressive, metastasis-prone disease. Enter Propanc's PRP-an investigational proenzyme therapy delivered intravenously. Unlike cytotoxic drugs that kill dividing cells broadly, PRP targets cancer stem cells, blocks metastasis by suppressing epithelial-mesenchymal transition, disrupts the tumor microenvironment, curbs angiogenesis, and boosts chemosensitivity-potentially making standard treatments more effective with far less toxicity. Preclinical data shines: greater than85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler profile. A small compassionate study extended survival from ~5.6 to 9 months in advanced cases. PRP vs. Current Treatment Options: Chemo: PRP could sensitize resistant tumors and cut doses/side effects. Targeted drugs: Broader attack on stem cells and spread, not just single mutations. Immunotherapy: May warm up "cold" pancreatic tumors by remodeling the microenvironment. Propanc is gearing up for a Phase 1b First-In-Human trial in 2026, backed by fresh funding, new patents, and FDA Orphan Drug status for pancreatic cancer.

Propanc Biopharma announced an update on corporate progress as of December 31, 2025. Corporate and R&D Highlights: Accelerates IP Momentum: Files Four Provisional Patent Applications - Strengthening Global Protection for Breakthrough Proenzyme Formulations; Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal. "We are pleased with the advancements made with our R&D programs and in particular, our lead asset PRP which we are preparing for our world-first, Phase 1b, First-In-Human study in advanced cancer patients," said James Nathanielsz, CEO of Propanc. "We are executing several activities in preparation for this pivotal study, which we believe will become a future breakthrough treatment for metastatic cancer from solid tumors, especially fast spreading tumors with a poor patient prognosis where few treatment options exist. Activities include partnering with GMP manufacturing and bio-analytical contract organizations to produce the drug product and validate the pharmacokinetics method for the upcoming pivotal study. In the meantime, we continue to build the foundation for sustained success by extending our scientific research through partner universities, which enables further patentable discoveries including new therapeutic indications that could elevate proenzyme technology to future blockbuster status."